ACTA2 and pulmonary fibrosis: R2M3-26 significantly decreased the Modified Ashcroft Score and percentage lung fibrosis (Fig. 3D, E, G), and R2M3-26 and RSPO2 treatments showed trended decreases in the Severity Score and ACTA2 levels (Fig. 3C, F, H).